novo nordisk semaglutide alzheimer trial GLP-1 Drug Fails to Quell Alzheimer's in Trials Semaglutide in early-stage Alzheimer's Disease

Neuropharmacology 136(Pt B):280286

What Makes Dual Agonists Unique in Obesity Treatment Dual agonists represent the next evolution in hormonal therapies for obesity

In 1957, Jean Stern physician and clinical pharmacologist published the results of a study on the antidiabetic properties of several biguanides

The Dosing Truth About Ipamorelin Here's the honest answer: the emphasis on 'daily dose' in most peptide discussions is fundamentally misplaced when talking about Ipamorelin

A 2021 study observed nearly 2,000 adults with excess body weight or obesity who didnt have diabetes

Glutathione research, by contrast, focuses primarily on its antioxidant and detoxification properties rather than direct weight loss outcomes